Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
November 2020
-
Key ReleaseNovartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor eventNovartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth…
-
New hope for treating inflammatory diseases of the kidney
Novartis researchers aim to preserve kidney function – and quality of life – for patients.
-
Media ReleaseNovartis secures exclusive rights for potential acute respiratory distress syndrome cell therapyNovartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other…
-
Media ReleaseNew data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseasesPivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIsELARA results for Kymriah® in relapsed or…
-
Predictive analytics could bring medicines to patients faster
Novartis researchers are using data to accelerate drug development.
-
Featured NewsAchieving 100% renewable electricity
Five virtual power purchase agreements with three developers expected to add more than 275 megawatts of clean power to the electrical grid.
-
Media ReleaseNovartis set to achieve 100% renewable electricity in its European operationsFive virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas…
-
Making Possible: Stepping toward a future with cell and gene therapy
These stories offer a glimpse into the lives of people touched by a new era of medicine.
-
Featured NewsLeading performance in sustainability
Novartis included in Dow Jones Sustainability World Index, with industry-leading performance in environmental and social reporting and human capital.
-
Media ReleaseResults from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2 Follows establishment of multi-disciplinary expert coalition and Novartis…
-
Media ReleaseNew Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and genderPooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female…
-
Featured NewsStudy suggests there may be two stages of fatal lung disease in COVID-19
NIBR translational immunologists and academic colleagues observe two distinct molecular patterns of disease progression in lung tissue samples.
Pagination
- ‹ Previous page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- …
- 152
- › Next page